Taiwan's Medigen says it seeks usage approval for COVID-19 vaccine candidate

Taiwan's Medigen says it seeks usage approval for COVID-19 vaccine candidate

Taiwan has struggled to secure enough vaccine doses for its 23 million people
Taiwan has struggled to secure enough COVID-19 vaccine doses for its 23 million people. (File photo: AFP/Sam Yeh)

TAIPEI: Taiwan's Medigen Vaccine Biologics said on Thursday (Jun 10) that it was seeking a speedy emergency use authorisation, or EUA, from the government for its COVID-19 vaccine candidate after safely completing phase two trials.

Developing its own vaccine has been a major goal of Taiwan's government, though it also has ordered about 20 million shots from Moderna, AstraZeneca and the COVAX global sharing scheme for lower income countries.

Only about 3 per cent of Taiwan's 23.5 million people have received at least one shot, with further supplies held up by global production problems, as the island deals with a spike in domestic cases after months of relative safety.

Medigen's chief executive, Charles Chen, told a briefing they were pleased with the phase two results and would be submitting an EUA request to Taiwan's food and drug administration soon.

READ: Taiwan warns of COVID-19 vaccine delays, cases stabilise

"Safety is very important, and our vaccine is very safe," he said, adding he was "very optimistic" about getting the authorisation.

Chen said that ultimately the company was preparing to produce 100 million doses, and export them to the small number of countries with which Chinese-claimed Taiwan has diplomatic relations after the vaccine gets international regulatory approval.

Taiwan's government last month signed deals with Medigen and another local firm, United Biomedical for 5 million doses each. It has agreements for another 5 million each, for a total of 20 million shots.

Medigen says that more than 4,000 people participated in its second phase clinical trial and received two shots, and that it had seen no serious adverse reactions, with a placebo given to one in every seven participants.

READ: Taiwan activists slam 'discriminatory' COVID-19 migrant curbs 

The recombinant protein vaccine has been developed in collaboration with the National Institutes of Health in the United States.

Taiwan's government hopes to start administering the domestically developed vaccines next month.

The government, however, has come under criticism from opposition parties after President Tsai Ing-wen pledged last month to start administering domestically developed vaccines in July before results of the second clinical trial were released.

Tsai later said her government would strictly scrutinise the process under international scientific norms and put safety first.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/dv

Bookmark